Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Patent Expiration
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic is Used for correcting hypophosphatemia in adults and pediatric patients 12 years of age and older. It was first introduced by Cmp Development Llc
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Patents
Given below is the list of patents protecting Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Potassium Phosphates | US10632150 | Potassium phosphates composition for injection | Apr 19, 2039 | Cmp Dev Llc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Generics
Several generic applications have been filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. The first generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic was by American Regent Inc and was approved on Oct 2, 2023. And the latest generic version is by Somerset Therapeutics Llc and was approved on Jul 11, 2024.
Given below is the list of companies who have filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic generic.
1. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 2 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 11, 2024 |
| 3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 11, 2024 |
2. AMNEAL
Amneal Eu Ltd has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 10, 2023 |
| 3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 10, 2023 |
| 11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 10, 2023 |
3. AM REGENT
American Regent Inc has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Am Regent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 2, 2023 |
| 3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 2, 2023 |
| 11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 2, 2023 |